Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-05-22
1998-03-31
Hutzell, Paula K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 530350, A61K 3817
Patent
active
057338752
ABSTRACT:
The present invention is directed to the use of glial-derived neurotrophic factor (GDNF) to inhibit or prevent seizure activity. The methods of the present invention are accomplished by administering GDNF to patients having or potentially having a neurodegenerative disorder such as epilepsy. Pharmaceutical compositions containing a therapeutically effective amount of GDNF in a pharmaceutically acceptable carrier are also provided.
REFERENCES:
Altar et al. (1992), `Brain-derived neuotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo`, Proc. Natl. Acad. Sci. U.S.A. 89:11347-11351.
Ben-Ari et al. (1981), `Electrographic, Clinical and Pathological Alterations Following Systemic Administration of Kainic Acid, Bicuculline or Pentetrazole: Metabolic Mapping Using the Deoxyglucose Method with Special Reference to the Pathology of Epilepsy`, Neurosci. 6(7):1361-1391.
Ben-Ari (1985), `Limbic Seizure and Brain Damage Produced by Kainic Acid: Mechanisms and Relevance to Human Temporal Lobe Epilepsy`, Neurosci. 14(2):375-403.
Berlove et al. (1991), Basic Fibroblast Growth Factor (bFGF) Protects Against Ischemic Neuronal Death In Vivo`, Soc. Neurosci. Abstr. 17:1267; abstract No. 501.13.
Cheng et al. (1991), `NGF and bFGF Protect Rat Hippocampal and Human cortical Neurons against Hypoglycemic Damage by Stabilizing Calcium Homeostasis`, Neuron 7:1031-1041.
Dingledine et al. (1988), `Amino Acid Receptors and Uptake Systems in the Mamalian Central Nervous System`, Neurobiology 4:1-96.
Ernfors et al. (1991), `Increased Levels of Messenger RNAs for Neutrotrophic Factors in the Brain during Kindling Epileptogenesis`, Neuron 7:165-176.
Follesa et al. (1994), `Regional and Temporal Pattern of Expression of Nerve Growth Factor and Basic Fibroblast Growth Factor mRNA in Rat Brain Following Electroconvulsive Shock`, Exp. Neurol. 127:37-44.
Gall et al. (1991), `Kainic acid-induced seizures stimulate increased expression of nerve growth factor mRNA in rat hippocampus`, Mol. Brain Res. 9:113-123.
Hajnal et al. (1992), `Feeding Disturbances and EEG Activity Changes After Amygdlaoid Kainate Lesions in the Rat`, Brain Res. Bull. 29:209-916.
Hefti et al. (1989), `Function of Neurotrophic Factors in the Adult and Aging Brain and Their Possible Use in the Treatment of Neurodegenerative Diseases`, Neurobiol. Aging 10:515-588.
Hudson et al. (1993), `In Vivo Activity of GDNF, A Glial-Cell-Line-Derived Neurotrophic Factor, on the Rat Nigrostriatal Dopamine System`, Soc. Neurosci. Abstr. 19:652; abstract No. 275.5.
Humpel et al (1994), `Neurons of the hippocampal formation express glial cell line-derived neurotrophic factor messenger RNA in response to kainate-induced excitation`, Chem. Abstr. 120:21, Abstract No. 262210k.
Humpel et al. (1994) `Neurons of the Hippocampal Formation Express Glial Cell Line-Derived Neurotrophic Factor Messenger RNA in Response to Kainate-Induced Excitation`, Neurosci. 59(4):791-795.
Lin et al. (1990), `Isolation and Characterization of Ciliary Neurotrophic Factor from Rabbit Sciatic Nerves`, J. Biol. Chem. 265(15):8942-8947.
Lin et al. (1993), `GDNF: A Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons`, Science 260:1130-1132.
Lin et al. (1994), `Purification and Initial Characterization of Rat B49 Glial Cell Line-Derived Neurotrophic Factor`, J. Neurochem. 63(2):758-768.
Lothman & Collins (1981), Kainic Acid Induced Limbic Seizures: Metabolic, Behavioral, Electroencephalographic and Neuropathological Correlates`, Brain Res. 218:299-318.
Martin et al. (1994), `rhGDNF Prevents Kainic Acid Induced Seizures and the Associated Neuronal Cell Death`, Soc. Neurosci. Abstr. 20(1-2): p. 442.
Martin-Iverson et al. (1994), `Brain-derived Neurotrophic Factor and Neurotrophic-3 Activate Striatal Dopamine and Serotonin Metabolism and Related Behaviors: Interactions with Amphetamine`, J. Neurosci. 14(3):1262-1270.
Mattson et al. (1993), `Growth Factors Protect Neurons Against Excitotoxic/Ischemic Damage by Stabilizing Calcium Homeostasis`, Stroke 24(12):I136-I140.
McDonald et al. (1991), `Expression and characterization of recombinant human ciliary neurotrophic factor from Escherichia coli`, Biochem. Biophys. Acta 1090:70-80.
Miller et al. (1994), `Central Administration of rhGDNF Causes Augmentation of Dopaminergic Activity in vivo`, Soc. Neurosci. Abstr. 20:535.7.
Nadler (1981), `Kainic Acid as a Tool for the Study of Temporal Lobe Epilepsy`, Life Sci. 29:2031-2042.
Nadler (1989), `Seizures and Nueronal Cell Death in the Hippocampus`, The Hippocampus-New Vistas, (Alan R. Liss) pp. 463-481.
Schaar et al. (1993), `Regional and Cell-Specific Expression of GDNF in Rat Brain`, Exp. Neurol. 124:368-371.
Shigeno et al. (1991), `Amelioration of Delayed Neuronal Death in the Hippocampus by Nerve Growth Factor`, J. Neurosci. 11(9):2914-2919.
Shimohama et al. (1993), `Brain-derived neurotrophic factor pretreatment exerts a partially protective effect against glutamate-induced neurotoxicity in cultured rat cortical neurons`, Neurosci. Lett. 164:55-58.
Stasheff et al. (1989), NMDA Antagonists differentiate Epileptogenesis from Seizure Expression in an in Vitro Model`, Science 245:648-651.
Stromberg et al. (1993), `Glail Cell Line-Derived Neurotrophic Factor is Expressed in the Developing but Not Adult Striatum and Stimulates Developing Dopamine Neurons in Vivo`, Exp. Neurol. 124:401-412.
Tanaka et al. (1992), `Experimental Complex Partial Seizures Induced by a Microinjection of Kainic Acid Into Limbic Structures`, Prog. Neurobiol. 38:317-334.
Wong et al. (1986), `The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist`, Proc. Natl. Acad. Sci. U.S.A. 83:7104-7108.
Humpel et al., Neuroscience, vol. 59, pp. 791-795, 1994.
Schmidt-Kastner et al., Mol. Brain Res., vol. 26, pp. 325-330, 1994.
Amgen Inc.
Curry Daniel R.
Gucker Stephen
Hutzell Paula K.
Levy Ron K.
LandOfFree
Methods of using GDNF as a neuroprotective agent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using GDNF as a neuroprotective agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using GDNF as a neuroprotective agent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-51908